Infigratinib

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Infigratinib is an ofm drug catalogued in DrugCentral. It was first approved by the FDA in 2019. DrugCentral lists 32 molecular targets, including FGFR2, FGFR1 and FGFR3. Recorded indications include Unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion.

• Approval status: ofm (first approved 2019 by the FDA).
• Molecular targets: FGFR2, FGFR1, FGFR3 and SMO (32 listed in DrugCentral).
• Indications: Unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion.
• ATC code: L01EN03 (Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors).
• Molecular formula: C26H31Cl2N7O3; molecular weight 560.48 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion

Mechanism & targets

Molecular targets (32)

Target	Gene	Action	Activity
Fibroblast growth factor receptor 2	FGFR2	inhibitor	Activity 9.00
Fibroblast growth factor receptor 1	FGFR1	inhibitor	Activity 8.99
Fibroblast growth factor receptor 3	FGFR3	inhibitor	Activity 8.70
Smoothened homolog	SMO	unknown	Ki 7.33
Fibroblast growth factor receptor 4	FGFR4	inhibitor	Activity 7.21
Vascular endothelial growth factor receptor 2	KDR	inhibitor	IC50 6.74
Tyrosine-protein kinase Lyn	LYN	unknown	IC50 6.52
Fibroblast growth factor receptor 4, FGFR-4, EC 2.7.10.1	Fgfr4	unknown	IC50 6.27
Mast/stem cell growth factor receptor Kit	KIT	unknown	IC50 6.12
Tyrosine-protein kinase Yes	YES1	unknown	IC50 5.96
Vascular endothelial growth factor receptor 1	FLT1	unknown	IC50 5.82
Tyrosine-protein kinase Fyn	FYN	unknown	IC50 5.72
Angiopoietin-1 receptor	TEK	unknown	IC50 5.69
Vascular endothelial growth factor receptor 3	FLT4	unknown	IC50 5.68
Tyrosine-protein kinase ABL1	ABL1	unknown	IC50 5.64
Tyrosine-protein kinase Lck	LCK	unknown	IC50 5.60
Platelet-derived growth factor receptor alpha	PDGFRA	unknown	IC50 5.57
Tyrosine-protein kinase JAK2	JAK2	unknown	IC50 5.54
Macrophage-stimulating protein receptor	MST1R	unknown	IC50 5.54
Proto-oncogene tyrosine-protein kinase Src	SRC	unknown	IC50 5.53

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2019-06-28	FDA	—	QED THERAP	Yes

ATC classification

ATC code	Therapeutic hierarchy
L01EN03	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › PROTEIN KINASE INHIBITORS › Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Infigratinib is on its molecule page.

• Molecular formula: C₂₆H₃₁Cl₂N₇O₃
• Molecular weight: 560.48 g/mol
• CAS number: 872511-34-7
• InChIKey: QADPYRIHXKWUSV-UHFFFAOYSA-N
• PubChem CID: 53235510

CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Infigratinib used for?

DrugCentral lists the following indications for Infigratinib: Unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion.

How does Infigratinib work?

Its molecular targets in DrugCentral include FGFR2 (inhibitor), FGFR1 (inhibitor), FGFR3 (inhibitor) and SMO.

When was Infigratinib first approved?

Infigratinib was first approved by the FDA in 2019.

What is the chemical formula of Infigratinib?

Infigratinib has the molecular formula C26H31Cl2N7O3 and a molecular weight of 560.48 g/mol.

Sources

• DrugCentral drug card 5459 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1834657 — compound record and bioactivity
• PubChem CID 53235510 — chemical identifiers
• DrugBank DB11886 — drug record
• FDA UNII A4055ME1VK — substance identity
• DailyMed: FDA labels for Infigratinib — current prescribing information (label search)
• UniProt P21802 (FGFR2) — target protein
• UniProt P11362 (FGFR1) — target protein
• UniProt P22607 (FGFR3) — target protein
• UniProt Q99835 (SMO) — target protein
• UniProt P22455 (FGFR4) — target protein
• UniProt P35968 (KDR) — target protein

How this page is built: methodology · editorial policy & corrections.